Danish pharmaceutical company Lundbeck has entered a research collaboration with the Dutch biotech company to-BBB to develop antibodies for the treatment of diseases in the central nervous system (CNS), reports national daily newspaper Børsen. The aim is to create new forms of treatment targeted at diseases in the brain.
CSO of to-BBB, Pieter Gaillard says in a press release: "We are very pleased to collaborate with Lundbeck. To-BBB's brain delivery technology combined with Lundbeck's strong knowledge in this area of CNS disorders, could result in further progress to improve the lives of patients with devastating brain diseases."
The Dutch company writes that thanks to advances in biotechnology, therapeutic antibodies have become a well-established form of treatment of a number of systemic diseases. The problem in relation to CNS diseases is however that the blood-brain barrier (BBB) prevents delivery of many drug candidates to their disease target. To-BBB has developed what it describes as a safe technology for drug delivery to the brain termed G-technology. Lundbeck will not evaluate the technology in its labs.
Lundbeck is an international pharmaceutical company conducting research into, developing, manufacturing, marketing, selling and distributing pharmaceuticals for the treatment of neurological disorders, including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease and insomnia. The company is headquartered in Copenhagen and employs 5,500 people worldwide.